PMID- 26177280
OWN - NLM
STAT- MEDLINE
DCOM- 20160520
LR  - 20150720
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 7
DP  - 2015
TI  - Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in
      ovariectomized rats without diabetes.
PG  - e0132744
LID - 10.1371/journal.pone.0132744 [doi]
AB  - Recently, a number of studies have demonstrated the potential beneficial role for
      novel anti-diabetic GLP-1 receptor agonists (GLP-1RAs) in the skeleton metabolism
      in diabetic rodents and patients. In this study, we evaluated the impacts of the 
      synthetic GLP-1RA Liraglutide on bone mass and quality in osteoporotic rats
      induced by ovariectomy (OVX) but without diabetes, as well as its effect on the
      adipogenic and osteoblastogenic differentiation of bone marrow stromal cells
      (BMSCs). Three months after sham surgery or bilateral OVX, eighteen 5-month old
      female Wistar rats were randomly divided into three groups to receive the
      following treatments for 2 months: (1) Sham + normal saline; (2) OVX + normal
      saline; and (3) OVX + Liraglutide (0.6 mg/day). As revealed by micro-CT analysis,
      Liraglutide improved trabecular volume, thickness and number, increased BMD, and 
      reduced trabecular spacing in the femurs in OVX rats; similar results were
      observed in the lumbar vertebrae of OVX rats treated with Liraglutide. Following 
      in vitro treatment of rat and human BMSCs with 10 nM Liraglutide, there was a
      significant increase in the mRNA expression of osteoblast-specific
      transcriptional factor Runx2 and the osteoblast markers alkaline phosphatase
      (ALP) and collagen alpha1 (Col-1), but a significant decrease in peroxisome
      proliferator-activated receptor gamma (PPARgamma). In conclusion, our results
      indicate that the anti-diabetic drug Liraglutide can exert a bone protective
      effect even in non-diabetic osteoporotic OVX rats. This protective effect is
      likely attributable to the impact of Liraglutide on the lineage fate
      determination of BMSCs.
FAU - Lu, Nan
AU  - Lu N
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Sun, Hanxiao
AU  - Sun H
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Yu, JingJia
AU  - Yu J
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Wang, Xiaojing
AU  - Wang X
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Liu, Dongmei
AU  - Liu D
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Zhao, Lin
AU  - Zhao L
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Sun, Lihao
AU  - Sun L
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Zhao, Hongyan
AU  - Zhao H
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Tao, Bei
AU  - Tao B
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
FAU - Liu, Jianmin
AU  - Liu J
AD  - Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and
      Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic
      Diseases, Shanghai 200025, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150715
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anabolic Agents)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (PPAR gamma)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Adipogenesis/*drug effects
MH  - Anabolic Agents/*pharmacology
MH  - Animals
MH  - Bone Density/drug effects
MH  - Bone and Bones/*drug effects/physiology
MH  - Cells, Cultured
MH  - Diabetes Mellitus/metabolism
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Liraglutide/*pharmacology
MH  - Male
MH  - Mesenchymal Stromal Cells/cytology/*drug effects
MH  - Osteoblasts/drug effects
MH  - Osteogenesis/*drug effects
MH  - Osteoporosis/pathology/physiopathology/prevention & control
MH  - Ovariectomy
MH  - PPAR gamma/metabolism
MH  - Rats
MH  - Rats, Wistar
PMC - PMC4503456
EDAT- 2015/07/16 06:00
MHDA- 2016/05/21 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/01/20 00:00 [received]
PHST- 2015/06/17 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2016/05/21 06:00 [medline]
AID - 10.1371/journal.pone.0132744 [doi]
AID - PONE-D-15-00361 [pii]
PST - epublish
SO  - PLoS One. 2015 Jul 15;10(7):e0132744. doi: 10.1371/journal.pone.0132744.
      eCollection 2015.